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A B S T R A C T
Purpose
The biology of HIV-associated cancers may differ depending on immunologic and virologic context
during development. Therefore, an understanding of the burden of Kaposi’s sarcoma (KS) and non-
Hodgkin lymphoma (NHL) relative to antiretroviral therapy (ART), virologic suppression, and CD4
count is important.
Patients and Methods
KS and NHL diagnoses during 1996 to 2011 were identified among patients with HIV infection in
eight clinical cohorts in the United States. Among patients in routine HIV clinical care, the proportion
of cases in categories of ART use, HIV RNA, and CD4 count at diagnosis were described across
calendar time. Person-time and incidence rates were calculated for each category.
Results
We identified 466 patients with KS and 258 with NHL. In recent years, KS was more frequently
diagnosed after ART initiation (55% in 1996 to 2001 v 76% in 2007 to 2011; P-trend = .02). The
proportion of patients with NHL who received ART was higher but stable over time (83% overall;
P-trend = .81). An increasing proportion of KS and NHL occurred at higher CD4 counts (P, .05 for KS
and NHL) and with undetectable HIV RNA (P , .05 for KS and NHL). In recent years, more person-
timewas contributed by patients who received ART, had high CD4 counts and had undetectable HIV
RNA, whereas incidence rates in these same categories remained stable or declined.
Conclusion
Over time, KS and NHL occurred at higher CD4 counts and lower HIV RNA values, and KS occurred
more frequently after ART initiation. These changes were driven by an increasing proportion of pa-
tientswith HIVwho received effective ART, had higher CD4 counts, and had suppressedHIV RNA and
not by increases in cancer risk within these subgroups. An improved understanding of HIV-associated
cancer pathogenesis and outcomes in the context of successful ART is therefore important.
J Clin Oncol 34:3276-3283. © 2016 by American Society of Clinical Oncology
INTRODUCTION
People with HIV infection have a highly elevated
risk of Kaposi’s sarcoma (KS) and non-Hodgkin
lymphoma (NHL)1 related to loss of immunologic
control of human herpesvirus-8 and Epstein-Barr
virus, respectively.2,3 With widespread use of ef-
fective antiretroviral therapy (ART), risk has de-
clined dramatically in the HIV population.4,5
However, KS and NHL incidence remains much
higher than in the general population,6 and eleva-
tions may persist after patients with HIV infection
have achieved virologic suppression and immune
recovery.7 These HIV-associated cancers also con-
tribute substantially to the total US KS and
NHL burden.8
Trends in earlier ART initiation and in-
creased emphasis on linkage and retention into
care have changed the characteristics of the HIV
population. Among US patients with HIV in
clinical care in 2008, 83% had been prescribed
ART and 72% had suppressed levels of HIV RNA
compared with 74% prescribed ART and 46%
with suppressed HIV RNA in 2000.9 Given this
shift, the fraction of KS and NHL cases occurring
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among patients with HIV administered effective ART may be
increasing despite the benefits of ART.
Because viral suppression and immune recovery combat KS
and NHL development, the biology of cancers that arise despite
effective ART likely differ from those that develop in patients with
HIV and uncontrolled viremia and severe immunosuppression. An
understanding of the KS and NHL burden among people with HIV
infectionwho have received effective ART is important because these
cancers may require different therapeutic approaches. In this study,
we characterize KS and NHL diagnoses relative to ARTuse, virologic
suppression, and CD4 count in a large clinical HIV population.
PATIENTS AND METHODS
The study population included adults with HIV infection from eight US HIV
clinical cohorts that comprise the Centers for AIDS Research Network of
Integrated Clinical Systems (CNICS) and followed from 1996 to 2011.10 This
calendar period spans from the beginning of widespread combination ART
availability to the last year of systematic identification of cancer diagnoses in
CNICS. CNICS collects data through electronic medical records, including
information on demographics, ARTuse, diagnoses, CD4 count, andHIVRNA
measurements. Cancer diagnoses have been verified through a standardized
process.11 Each CNICS site obtained local institutional review board approval.
Demographic characteristics were described for patients with KS and
NHL who received a diagnosis on or after a first visit at a CNICS site over
three calendar periods (1996 to 2001, 2002 to 2006, and 2007 to 2011).
Diagnoses were categorized as having occurred in or out of routine clinical
care. Start of routine clinical care was defined as the date when the second
of two consecutive HIV outpatient visits occurred $ 1 month apart and
within 6 months. Routine clinical care was considered to continue as long
as clinical visits were not. 12months apart. If a patient went. 12months
without a visit, the case was recategorized as out of routine clinical care
until the original two-visit criterion was met again. Trends in the pro-
portion of KS and NHL cases diagnosed in routine care across calendar
periods were evaluated by Cochran-Armitage test.
We restricted further analyses to time in routine clinical care because
we could obtain reliable information on ART and laboratory measures
during this time only. KS and NHL cases diagnosed during routine care
were characterized based on ARTuse, immune status, and virologic status
at the time of cancer diagnosis. We also specifically characterized cases of
diffuse large B-cell lymphoma (DLBCL), the most common NHL subtype.
ART initiation was defined as the first concurrent use of three or more
different antiretroviral medications. ARTstatus was categorized as no ART,
ART initiation , 6 months prior (when immune reconstitution in-
flammatory syndrome is most likely),12 or ART initiation $ 6 months
prior. Immune status at cancer diagnosis was based on the latest CD4 count
within 6 months before cancer diagnosis. Virologic status was based on the
latest HIV RNA value 3 to 9 months before cancer diagnosis. We assessed
HIV RNA measurements 3 months earlier than CD4 counts because HIV
RNA is highly variable over short periods, and values closer to cancer
diagnosis may be affected by management changes during diagnostic
evaluation for cancer. If CD4 count or HIV RNAvalues were unavailable in
these windows, the cases were excluded from analyses of those charac-
teristics (, 15% of cases were excluded for this reason).
We described the proportion of KS and NHL cases in each ART category
as well as in CD4 count and HIV RNA categories across calendar periods. We
evaluated changes in the proportion of cases in each category across periods by
using x2 as a global test for differences and the Cochran-Armitage test to
evaluate trends for particular categories over time. BecauseCD4 count andHIV
RNAcan be evaluated as continuous variables, changes in themean CD4 count
and HIV RNA (log10-transformed) were also described nonparametrically by
using LOWESS curves,13 and trends were evaluated with linear regression.
To evaluate whether changes in the characteristics of cancer cases
resulted from changes in the underlying HIV population or changes in
cancer risk, we divided person-time in routine clinical care into the
aforementioned ART, CD4 count, and HIV RNA categories. Person-time
was used to calculate KS and NHL incidence rates, and Poisson regression
was used to evaluate time trends in incidence.
Standardized incidence ratios were calculated within categories that
compared observed cancer counts with expected counts. Expected counts
were calculated within strata of age, sex, and race by multiplying follow-up
time observed in each stratum by stratified incidence rates in the general
population obtained from SEER cancer registries.14 KS incidence rates
were based on 1973 to 1979 SEER data because subsequent rates are heavily
influenced by the HIV epidemic.8
RESULTS
Among 24,901 patients in CNICS during 1996 to 2011, there were
466 KS diagnoses and 258 NHL diagnoses, including 135 DLBCL
diagnoses. Most cases were among white men (Table 1). The
Table 1. Patients With Kaposi’s Sarcoma and Non-Hodgkin Lymphoma Diagnosed in the Centers for AIDS Research Network of Integrated Clinical Systems From
1996 to 2011
Patient Characteristics at Cancer Diagnosis
Kaposi’s Sarcoma, No. (%) Non-Hodgkin Lymphoma, No. (%)
1996-2001 2002-2006 2007-2011 1996-2001 2002-2006 2007-2011
Total 127 197 142 75 109 74
Sex
Female 4 (3) 8 (4) 4 (3) 11 (15) 12 (11) 9 (12)
Male 123 (97) 189 (96) 138 (97) 64 (85) 97 (89) 65 (88)
Median age at diagnosis (IQR) 37 (33-43) 40 (36-44) 42 (35-47) 40 (37-46) 42 (37-47) 46 (38-50)
Race*
White 89 (75) 122 (65) 95 (67) 46 (67) 56 (52) 46 (62)
Black 22 (19) 50 (27) 23 (16) 21 (30) 36 (34) 18 (24)
Other 8 (7) 16 (9) 24 (17) 2 (3) 15 (14) 10 (14)
Diagnosis during routine clinical care†
Yes 41 (32) 85 (43) 70 (49) 42 (56) 61 (56) 47 (64)
No 86 (68) 112 (57) 72 (51) 33 (44) 48 (44) 27 (36)
Abbreviation: IQR, interquartile range.
*Seventeen patient cases of Kaposi’s sarcoma and eight patient cases of non-Hodgkin lymphoma are missing information on race.
†Routine clinical care was defined as starting when two HIV outpatient visits occurred that were $ 1 month and , 6 months apart and continuing for as long as HIV
outpatient visits occurred at least every 12 months.
www.jco.org © 2016 by American Society of Clinical Oncology 3277
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Fig 1. Antiretroviral therapy (ART), immune, and virologic status of patientswithHIV in routine clinical carewhowere diagnosedwith Kaposi’s sarcoma and non-Hodgkin lymphoma.
(A) and (B) The proportion of Kaposi’s sarcoma and non-Hodgkin lymphoma patient cases that occurred at various times relative to ART initiation over three calendar periods. (C) and (D)
The distribution of CD4 counts at diagnosis of Kaposi’s sarcoma and non-Hodgkin lymphoma across time, including a LOWESScurve to illustrate the smoothed trend over time. (E) and
(F) ThedistributionofHIVRNAvalueson the log10 scale at diagnosisofKaposi’s sarcomaandnon-Hodgkin lymphomaacross time, including aLOWESScurve.ARTstartwasdefinedas
the first date at which there was concurrent use of at least three different antiretroviral medications. CD4 counts at cancer diagnosis were defined as the most recent values within
6months before cancer diagnosis. HIVRNAmeasurements at cancer diagnosiswere defined as themost recent values 3 to 9months before cancer diagnosis. HIVRNAvalues below
the detection limit were randomly assigned a value between the detection limit and zero. Although cancers were ascertained starting in 1996, the first patient with non-Hodgkin
lymphoma in the Centers for AIDS Research Network of Integrated Clinical Systems with an HIV RNA measurement 3 to 9 months before diagnosis was observed in 1998.
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median age at cancer diagnosis increased across time from 37 years
for KS and 40 years for NHL during 1996 to 2001 to 42 years for KS
and 46 years for NHL during 2007 to 2011 (Table 1).
Among KS cases, 42% (n = 196) were diagnosed during
routine clinical care, with the proportion increasing over time from
32% in 1996 to 2001 to 49% in 2007 to 2011 (P-trend = .005;
Table 1). Among NHL cases, 58% (n = 150) were diagnosed during
routine clinical care. This proportion did not change significantly
across time (P-trend = .354). In the most recent calendar period,
64% of cases were diagnosed during routine care.
Among cases diagnosed during routine care, ART status at
diagnosis changed over time for KS (P = .019) but not for NHL
(P = .809). Although only 26% of KS diagnoses occurred$ 6months
after ART initiation during 1996 to 2001, most KS cases were
diagnosed $ 6 months after ART initiation in the later periods,
reaching 60% in 2007 to 2011 (P-trend = .008; Fig 1A). ForNHL, 68%
of all diagnoses occurred $ 6 months after ART initiation, and this
proportion did not change noticeably over time (Fig 1B).
The mean CD4 count at diagnosis increased with calendar
time for both KS (P = .001) and NHL (P , .001). For KS, this
increase was most notable during 2003 to 2008, whereas a general
increasing trend was observed over the entire period for NHL (Figs
1C and 1D). During 2007 to 2011, 15% of KS cases and 24% of
NHL cases were diagnosed at CD4 counts$ 500 cells/mL, whereas
fewer than one half were diagnosed at CD4 counts, 200 cells/mL.
The mean HIV RNA value (3 to 9 months before cancer
diagnosis) decreased over time for both KS and NHL (Figs 1E and
1F), but the decrease was significant only for NHL (P = .014 for
NHL; P = .087 for KS). During 2007 to 2011, 29% of KS cases and
51% of NHL cases were diagnosed when HIV RNAwas suppressed
(, 500 copies/mL).
For the 82 DLBCL cases diagnosed during care, patterns were
similar to those for NHL overall (Appendix Fig A1, online only). The
proportion of diagnoses occurring$ 6 months after ART initiation
did not change significantly over time (P = .616), but DBLCL di-
agnoses were made at higher CD4 counts and lower HIV RNA levels
in more recent calendar years (P-trend , .001 for CD4 count;
P-trend = .018 for HIV RNA; Appendix Fig A1). During 2007 to
2011, 85% of DLBCL diagnoses were made $ 6 months after ART
initiation, 26% were diagnosed at CD4 counts $ 500 cells/mL, and
67% were diagnosed when HIV RNA was suppressed.
We also observed calendar trends when examining the
underlying person-time of patients followed during routine
care. Across time, more person-time was contributed when
patients had received ART for $ 6 months and less by patients
who had not initiated ART (Fig 2A). In more recent calendar
years, more person-time was contributed by patients with
higher CD4 counts and lower HIV RNAvalues (Figs 2B and 2C).
During 2007 to 2011, 45% of person-time was contributed by
patients with CD4 counts . 500 cell/mL compared with 30% in
1996 to 2001. Similarly, 76% of person-time was contributed by
patients with suppressed HIV RNA in 2007 to 2011 compared
with 45% in 1996 to 2001.
Overall, KS and NHL incidence rates decreased 5% and 8%
per year, respectively, during 1996 to 2011 (incidence rate ratios,
0.95 and 0.92 per year, respectively; Table 2). KS incidence de-
creased across time among patients who had not received ARTand
increased among those with HIV RNA values between 500 and
50,000 copies/mL. KS incidence did not significantly change for
any other ART, CD4 count, or HIV RNA category, although
a borderline decrease was observed among patients with HIV
RNA, 500 copies/mL (Table 2). NHL incidence decreased among
patients who received ART for. 6months, among those with CD4
counts , 200 cells/mL, and among those with HIV RNA values
, 500 copies/mL (Table 2). No changes in NHL incidence over time
were observed for other ART, CD4 count, or HIV RNA categories.
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Fig 2. Proportion of person-time contributed to each antiretroviral therapy (ART),
CD4 count, and HIV RNA category by calendar period among patients with HIV in
routine clinical care. Person-time categories are based on follow-up of the entire
Centers for AIDS Research Network of Integrated Clinical Systems HIV population
in routine clinical care and were time updated to account for changes in (A) ART
status, (B) CD4 count, and (C) HIV RNA values.
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Across all calendar periods, KS incidence in every ART, CD4
count, and HIV RNA category was higher than general population
rates (Table 3). Compared with the general US population, KS
incidence in 2007 to 2011 was 710 times higher among those who
received ART for$ 6 months, 430 times higher among those with
CD4 counts $ 500 cells/mL, and 430 times higher among those
with HIV RNA , 500 copies/mL. NHL incidence was also higher
than general population rates in almost every category across all
periods. Compared with the general population, NHL incidence
in 2007 to 2011 was 3.4 times higher among those who received
ART for $ 6 months, 3.1 times higher among those with CD4
counts $ 500 cells/mL, and 2.9 times higher among those with
HIV RNA , 500 copies/mL.
DISCUSSION
Among US patients with HIV infection, the clinical context inwhich
KS and NHL occur has changed considerably during the effective
ARTera. Since 1996, more cases have been diagnosed after entry into
routine clinical care, with 64% of NHL cases and 49% of KS cases
diagnosed during routine care in 2007 to 2011. As anticipated, the
overall incidence of KS andNHL decreased over calendar time, likely
due to increasing use and effectiveness of ART. However, more cases
were diagnosed among patients who either received ART, had high
CD4 counts, or had suppressed HIV RNA. In fact, in 2007 to 2011,
most cases occurred$ 6 months after ART initiation and in patients
with CD4 counts $ 200 cell/mL. For these cancers, new clinical
approaches may be needed because the clinical presentation,
treatment response, and prognosis likely differ from KS and NHL
diagnosed in the setting of severe immunosuppression.
The growing fraction of cancers diagnosed during routine
clinical care likely reflects the larger proportion of the HIV pop-
ulation engaged in care in more recent times. For example, among
US individuals with HIV infection entering care, an estimated 82%
were retained in routine care in 2008 compared with 61% in 2000.15
Engagement in routine care could reduce cancer risk by encouraging
ART initiation and adherence, and one might anticipate that en-
gagement in care would facilitate detection of cancers at an early
stage, which would lead to a facilitation of treatment. Because our
populationwas defined by attendance at an HIV clinic, we could not
obtain information on cancers among people who never visit an
HIV clinic. Thus, we likely underestimated the total proportion of
cancers in patients outside routine care and could not calculate
accurate incidence rates in these patients.
For KS and NHL diagnosed during routine care, several
patient characteristics changed over calendar time that reflect
changes in treatment of the underlying HIV population. The
proportion of KS cases diagnosed among patients who received
ART increased not because KS incidence increased in patients who
Table 2. Incidence Rates of Kaposi’s Sarcoma and Non-Hodgkin Lymphoma Among Patients With HIV in Routine Clinical Care
Time-Updated Patient Characteristics
Incidence Rate (per 100,000 person-years) by
Calendar Period
IRR (per increasing calendar year) P-Trend1996-2001 2002-2006 2007-2011
Kaposi’s sarcoma
Total 243.7 232.2 168.1 0.95 .003
ART status
No ART 501.5 373.8 323.4 0.94 .043
ART , 6 months 733.8 1,040.1 795.6 1.00 .999
ART $ 6 months 88.3 164.0 119.4 1.01 .988
CD4 count (cells/mL)
, 200 674.2 816.7 609.7 0.98 .540
200-349 129.2 234.2 255.6 1.03 .565
350-499 36.7 114.0 136.7 1.05 .461
$ 500 46.1 36.2 61.5 1.05 .528
HIV RNA (copies/mL)
. 50,000 729.0 1,088.9 967.8 1.01 .660
500-50,000 141.5 166.6 356.6 1.10 .037
, 500 152.3 104.3 85.7 0.93 .051
Non-Hodgkin lymphoma
Total 249.6 166.6 112.9 0.92 , .001
ART status
No ART 200.6 186.9 202.1 0.99 .902
ART , 6 months 467.0 485.4 331.5 0.95 .385
ART $ 6 months 238.4 146.9 91.0 0.90 , .001
CD4 count (cells/mL)
, 200 855.7 539.0 336.4 0.93 .012
200-349 96.9 87.8 180.4 1.04 .537
350-499 36.7 156.7 85.9 0.98 .757
$ 500 23.1 63.4 67.7 1.03 .644
HIV RNA (copies/mL)
. 50,000 729.0 518.5 414.8 0.94 .165
500-50,000 101.1 230.6 231.8 1.05 .335
, 500 228.4 83.4 78.5 0.90 .004
Abbreviations: ART, antiretroviral therapy; IRR, incidence rate ratio.
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received ART but because of the growing fraction of the HIV
population administered ART. Similar patterns were seen for KS
and NHL with respect to HIV RNA and CD4 count (ie, a larger
proportion of cases among patients with suppressed HIV RNA and
high CD4 counts), even as KS and NHL incidence declined or
remained constant in these strata. Again, these trends resulted from
the consistently increasing fraction of the HIV population who live
with virologic control and immune competence. Although we
evaluated trends in ARTuse, HIV RNA, and CD4 count separately,
these clinical characteristics and the changes in the underlying HIV
population are inherently related. Improvements in ARTaccess and
earlier initiation lead to earlier suppression of HIV RNA and,
ultimately, higher CD4 counts.
Other changes in the HIV population have influenced the
clinical characteristics of cancer cases. For instance, cancers in the
HIV population are typically diagnosed at younger ages than in the
general population, which reflects the younger age distribution of
the HIV population.16 Nonetheless, both KS and NHL arose at
older ages in more recent calendar years in the current study. As the
HIV population continues to age, the age distribution of cancer
cases will likely continue to shift to older ages. Furthermore, one
would expect to see more cancers etiologically related to aging.
Changing clinical characteristics of these cancers may also
reflect changing biology. For example, cancers that develop in
patients with HIV infection after immune recovery may manifest
genetic or epigenetic changes that facilitate evasion from the
immune system, whereas cancers that arise in more immuno-
suppressed populations may not face the same degree of immune
selection and may not manifest these changes.17 Given that
human herpesvirus-8 and Epstein-Barr virus are genetically
heterogeneous,18,19 another possibility is that patients in whom KS
or NHL develop after immune reconstitution may be infected with
more pathogenic strains. For NHL, the distribution of subtypes has
changed over time, with DLBCL and lymphoma of the CNS making
up a smaller proportion of diagnoses in more recent years, whereas
Burkitt lymphoma and other lymphoma subtypes now make up
a larger proportion of diagnoses.20 However, when we limited
analyses to one subtype, DLBCL, we still observed changes in the
immunologic and virologic context of the diagnoses over time. As
the HIV population ages, KS and NHL cases may resemble cases
seen in elderly populations.21 Among patients administered ART,
the presence of circulating T cells with immunosenescent pheno-
types is associated with a KS diagnosis, which indicates that cancer-
promoting mechanisms related to aging may be important.22
In this study, even patients with HIV who received ART, had
high CD4 counts, or had suppressed HIV RNA had higher KS and
NHL incidence than the general population. This could be due to
lingering weaknesses in the immune system. For instance, although
ART initiation corresponds with gradual increases in immune
responses to human herpesvirus-8,23-25 these responses might not
be as robust as in individuals with no history of immunosup-
pression. HIV could also have persistent direct effects on KS and
NHL risk because the HIV latent reservoir is not eliminated with
ART use. HIV viremia after ART initiation predicts NHL risk
independently of CD4 count,26 and recent studies provide evidence
that HIV proteins may directly encourage B-cell clonogenicity.27
Table 3. Standardized Incidence Ratios for Kaposi’s Sarcoma and Non-Hodgkin Lymphoma Among White and Black Patients With HIV in Routine Clinical Care
Time-Updated Patient Characteristics
Standardized Incidence Ratio (95% CI)
1996-2001 2002-2006 2007-2011
Kaposi’s sarcoma
ART status
No ART 5,000 (3,100 to 7,600) 3,200 (2,000 to 4,700) 3,100 (1,900 to 4,700)
ART , 6 months 9,200 (5,200 to 15,000) 12,000 (7,200 to 18,000) 6,200 (3,200 to 11,000)
ART $ 6 months 740 (370 to 1,300) 1,200 (900 to 1,500) 710 (530 to 930)
CD4 count (cells/mL)
, 200 5,900 (4,000 to 8,600) 6,400 (4,900 to 8,200) 3,900 (2,700 to 5,400)
200-349 1,300 (450 to 3,000) 1,600 (970 to 2,500) 1,600 (980 to 2,400)
350-499 400 (21 to 1,900) 950 (470 to 1,700) 660 (330 to 1,200)
$ 500 550 (97 to 1,700) 310 (110 to 710) 430 (230 to 720)
HIV RNA (copies/mL)
. 50,000 7,500 (4,400 to 12,000) 10,000 (8,100 to 14,000) 9,200 (6,200 to 13,000)
500-50,000 1,300 (490 to 2,600) 1,500 (820 to 2,400) 3,000 (1,900 to 4,400)
, 500 1,500 (800 to 2,500) 700 (450 to 1,000) 430 (280 to 630)
Non-Hodgkin lymphoma
ART status
No ART 6.7 (2.3 to 15) 11 (5.9 to 18) 8.8 (4.1 to 17)
ART , 6 months 22 (8.5 to 45) 18 (6.1 to 41) 17 (5.8 to 39)
ART $ 6 months 12 (8.0 to 17) 7.0 (5.3 to 9.0) 3.4 (2.4 to 4.6)
CD4 count (cells/mL)
, 200 39 (27 to 54) 24 (17 to 33) 10 (5.5 to 17)
200-349 5.5 (1.5 to 14) 4.3 (1.9 to 8.5) 6.8 (3.7 to 12)
350-499 2.3 (0.12 to 11) 8.1 (4.5 to 13) 3.4 (1.5 to 6.7)
$ 500 0 (0 to 4.3) 3.2 (1.5 to 6.1) 3.1 (1.7 to 5.1)
HIV RNA (copies/mL)
. 50,000 35 (20 to 56) 27 (18 to 40) 19 (9.0 to 36)
500-50,000 6.5 (2.6 to 14) 12 (7.5 to 18) 10 (5.6 to 17)
, 500 5.8 (3.3 to 9.7) 3.7 (2.3 to 5.6) 2.9 (1.9 to 4.3)
Abbreviation: ART, antiretroviral therapy.
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Changes in the clinical context of these cancers may have
important implications for treatment and prognosis. For KS and
NHL cases diagnosed in the setting of uncontrolled HIV, initiation
of ART is a major component of cancer treatment.2 For KS, ART
alone can lead to significant regression, presumably due to im-
proved immune function and control of human herpesvirus-8.2
However, as the current study shows, KS andNHL develop inmany
patients despite ART, and intensification or other ART changes
may not be beneficial.28,29 For NHL, how the immunologic and
virologic context at diagnosis influences tumor biology and disease
aggressiveness currently is unclear. A previous CNICS study found
that patients with NHL diagnosed while receiving ART had worse
survival than those with NHL diagnosed before ART initiation.20
However, for HIV-associated NHL, and specifically DLBCL, pa-
tients with higher CD4 counts have been observed to have better
responses and improved survival.30,31 Further study could help to
determine whether associations reflect differences in patterns of
care or whether consistent predictors can be identified that cor-
respond to underlying biologic differences.
This study has limitations. Limited information was available
for cancers diagnosed outside routine clinical care; thus, the study
focused mostly on cancers diagnosed during routine care. In
addition, although the study population was large, we lacked
enough cases to cross-classify them according to ART, HIV RNA
measurement, and CD4 count. Furthermore, the CNICS sites are
geographically diverse but are all based in large US academic
medical centers, which may differ from other HIV care settings.32
This study also has important strengths. We assessed cancer
diagnoses across a large multisite cohort that has systematically
yielded important clinical characteristics, including ART use,
CD4 counts, and HIV RNA measurements. Cancer diagnoses in
CNICS were verified through a standardized and comprehensive
process. Furthermore, because of the long follow-up in CNICS,
we could characterize cancer diagnoses over an extended span of
calendar time.
In conclusion, KS and NHL presented a continued burden in
the HIV population in the modern ART era, but presenting
characteristics for these malignancies are changing. In the United
States, more cases are diagnosed while patients are in routine care,
receive ART, have a relatively intact immune system, and have
suppressed HIV replication. These changes largely reflect the
dramatic changes over time in treatment of the underlying HIV
population. In the future, more studies are needed to understand
whether KS and NHL cases that arise during ART use differ bi-
ologically from cases that arise during severe immunosuppression
and uncontrolled HIV replication. If biologic differences are
demonstrated, they may suggest different approaches to effectively
prevent and treat these cancers in the modern ART era.
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Fig A1. Antiretroviral therapy (ART), immune, and virologic status of patientswith HIV in routine clinical carewhowere diagnosedwith diffuse large B-cell lymphoma (DLBCL). (A) The
proportionofDLBCLpatient cases that occurredat various times relative toART initiationover threecalendar periods. (B) ThedistributionofCD4counts at diagnosisofDLBCLacross time,
including a LOWESS curve to illustrate the smoothed trend over time. (C) The distribution of HIV RNA values on the log10 scale at diagnosis of DLBCL across time, including a LOWESS
curve. ART start was defined as the first date atwhich therewas concurrent use of at least three different antiretroviralmedications. CD4 counts at cancer diagnosiswere defined as the
most recent valueswithin 6months before cancer diagnosis.HIVRNAmeasurements at cancer diagnosisweredefinedas themost recent values3 to9monthsbefore cancer diagnosis.
HIV RNAvalues below the detection limitwere randomly assigned a value between the detection limit and zero. Although cancerswere ascertained starting in 1996, the first patientwith
DLBCL in the Centers for AIDS Research Network of Integrated Clinical System with an HIV RNA measurement 3 to 9 months before diagnosis was observed in 1998.
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